NTRA News
ESMO 2026 Presentations Deepen the Evidence Base for Nateras Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 2326 in Madrid, Spain.New evidence...
Business Wire
ESMO 2026 Presentations Deepen the Evidence Base for Nateras Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 2326 in Madrid, Spain.New evidence...
Business Wire
Nateras Signatera MRD Test Named to TIMEs List of the Best Inventions of 2026
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIMEs Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIMEs Best Inventions...
Business Wire
Natera Gains 118.1% in a Year: What's Driving the Rally?
NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.
Zacks
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic...
Business Wire
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenue growth.
Zacks
Natera Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Natera (NASDAQ:NTRA) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
Benzinga APIs provide real-time access to earnings call transcripts andread more...
Benzinga
FDA Grants Breakthrough Device Designation for Nateras Multi-Cancer Early Detection Assay
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies...
Business Wire
Natera Announces Randomized, Signatera-Guided Interventional Study in Melanoma
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients...
Business Wire
New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Nateras first participation at ASTRO and a significant step in...
Business Wire
$1000 Invested In Natera 10 Years Ago Would Be Worth This Much Today
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 29.68% on an annualized basis producing an average annual return of 43.44%. Currently, Natera has a market capitalization of $62.06 billion.read more...
Benzinga